AbbVie forecasts 2026 adjusted EPS of $13.87-$14.07 as it expects ~$67.6B revenue and Q3 EPS of $3.84-$3.88 (NYSE:ABBV)
· seekingalpha.com
AbbVie (ABBV) Q2 2026 earnings call insights: Skyrizi/Rinvoq growth, neuroscience catalysts, and Apogee deal dilution.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...